



US00D966300S

(12) **United States Design Patent** (10) **Patent No.:** **US D966,300 S**  
**Dobak, III et al.** (45) **Date of Patent:** **\*\* Oct. 11, 2022**

(54) **COMPUTER DISPLAY PANEL WITH A GRAPHICAL USER INTERFACE FOR A DERMATOLOGY REPORT**

(56) **References Cited**

U.S. PATENT DOCUMENTS

(71) Applicant: **DermTech, Inc.**, La Jolla, CA (US)

4,122,947 A 10/1978 Falla  
5,190,049 A 3/1993 Briggs et al.

(Continued)

(72) Inventors: **John Daniel Dobak, III**, La Jolla, CA (US); **Sarah Dion**, San Diego, CA (US); **Burkhard Jansen**, La Jolla, CA (US); **Jane Bue**, Vista, CA (US); **Claudia Ibarra**, Carlsbad, CA (US)

FOREIGN PATENT DOCUMENTS

WO WO-0010579 A1 3/2000  
WO WO-03001985 A2 1/2003

(Continued)

(73) Assignee: **DERMTECH, INC.**, La Jolla, CA (US)

(\*\*) Term: **15 Years**

OTHER PUBLICATIONS

(21) Appl. No.: **29/770,786**

Cerda et al. Geometry and Physics of Wrinkling. Phys Rev Lett 90(7):074302 (2003).

(Continued)

(22) Filed: **Feb. 16, 2021**

(51) **LOC (13) Cl.** ..... **14-04**

(52) **U.S. Cl.**

USPC ..... **D14/486**

(58) **Field of Classification Search**

USPC ..... D14/485-495

CPC .... G06F 3/048; G06F 3/0481; G06F 3/04812; G06F 3/04815; G06F 3/04817; G06F 3/0482; G06F 3/0483; G06F 3/0484; G06F 3/04842; G06F 3/04845; G06F 3/04847; G06F 3/0485; G06F 3/04855; G06F 3/0486; G06F 3/04886; G06Q 30/00; G06Q 30/02; G06Q 30/0237; G06Q 30/0238; G06Q 30/0239; H03J 1/00; H03J 1/0008; H03J 1/0016; H03J 1/0025; H04N 5/00; H04N 5/08; H04N 5/14; H04N 5/222; H04N 5/225; H04N 5/232; H04N 5/23222; H04N 5/23293; H04N 5/232933; H04N 5/232935; H04N 5/445; H04N 5/44504; H04N 5/45; H04N 21/00; H04N 21/234; H04N 21/431; H04N 21/4312; H04N 21/4314; H04N 21/4316; H04N 21/4532; H04N 21/4622; H04N 21/47; H04N 21/478; H04N 21/482;

(Continued)

(57) **CLAIM**

The ornamental design for a computer display panel with a graphical user interface for a dermatology report, as shown and described.


**DESCRIPTION**

FIG. 1 is a front view of a computer display panel with a graphical user interface for a dermatology report, showing our new design; and,

FIG. 2 is a front view of another embodiment of a computer display panel with a graphical user interface for a dermatology report, showing our new design.

The broken lines in the drawing represent portions of the computer display panel and the graphical user interface that form no part of the claimed design. The difference in crosshatch shading indicates a contrast of appearance and does not depict any particular color.

**1 Claim, 2 Drawing Sheets**



(58) **Field of Classification Search**  
 CPC ..... H04N 21/4884; H04N 21/4888; H04N  
 21/4856; H04N 21/485; H04N 21/6547  
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,921,396 A 7/1999 Brown, Jr.  
 D424,541 S \* 5/2000 Mugura ..... D14/486  
 D430,120 S \* 8/2000 Yasui ..... D14/488  
 6,106,732 A 8/2000 Johnston et al.  
 6,176,836 B1 1/2001 Trudil et al.  
 6,447,463 B1 9/2002 Borkowski  
 6,720,145 B2 4/2004 Rheins et al.  
 D504,440 S \* 4/2005 Luquet ..... D14/486  
 6,949,338 B2 9/2005 Rheins et al.  
 7,183,057 B2 2/2007 Benson  
 7,297,480 B2 11/2007 Vogt  
 D570,857 S \* 6/2008 Nguyen ..... D14/485  
 7,921,999 B1 4/2011 Kimball  
 7,989,165 B2 8/2011 Benson  
 D673,166 S 12/2012 Mori et al.  
 8,541,170 B2 9/2013 Kennedy et al.  
 8,938,684 B2 \* 1/2015 Guertler ..... G06F 3/0482  
 715/764  
 9,057,109 B2 6/2015 Chang  
 D786,282 S \* 5/2017 Donnelly ..... D14/486  
 D788,142 S \* 5/2017 Burke ..... D14/486  
 D816,697 S \* 5/2018 Ledford ..... D14/486  
 D816,699 S \* 5/2018 Ledford ..... D14/486  
 D816,700 S \* 5/2018 Bayer ..... D14/486  
 D824,402 S \* 7/2018 Donnelly ..... D14/485  
 D847,840 S \* 5/2019 Poschel ..... D14/486  
 10,407,729 B2 9/2019 Chang  
 D874,474 S \* 2/2020 Rognlie ..... D14/485  
 10,709,428 B2 7/2020 Palmer et al.  
 D900,130 S \* 10/2020 Matos ..... D14/485  
 D930,010 S \* 9/2021 Caudill ..... D14/485  
 D944,284 S \* 2/2022 Metzger ..... D14/487  
 D944,286 S \* 2/2022 Sanchez ..... D14/488  
 D946,017 S \* 3/2022 Courtney ..... D14/488  
 11,307,876 B1 \* 4/2022 Leonard, II ..... G06F 9/451  
 2002/0110824 A1 8/2002 Rheins et al.  
 2002/0115086 A1 8/2002 Rheins et al.  
 2002/0119471 A1 8/2002 Rheins et al.  
 2002/0127573 A1 9/2002 Rheins et al.  
 2002/0150918 A1 10/2002 Rheins et al.  
 2003/0045810 A1 3/2003 Borkowski  
 2006/0242554 A1 \* 10/2006 Gerace ..... G06Q 30/02  
 715/209  
 2007/0087323 A1 4/2007 Armitage et al.  
 2007/0243537 A1 10/2007 Tuck et al.  
 2007/0281314 A1 12/2007 Benson  
 2008/0138819 A1 6/2008 Vogt  
 2008/0200870 A1 \* 8/2008 Palmroos ..... G06F 3/0488  
 604/67  
 2008/0274908 A1 11/2008 Chang  
 2010/0086501 A1 4/2010 Chang et al.  
 2010/0105102 A1 4/2010 Hanes et al.  
 2010/0279877 A1 11/2010 Vogt  
 2011/0160080 A1 6/2011 Chang  
 2012/0065086 A1 3/2012 Benson  
 2013/0296185 A1 11/2013 Benson  
 2014/0154684 A1 6/2014 Chang  
 2014/0323331 A1 10/2014 Chang et al.  
 2015/0005184 A1 1/2015 Alsobrook et al.  
 2015/0259739 A1 9/2015 Chang et al.  
 2015/0361500 A1 12/2015 Ang et al.  
 2016/0024595 A1 1/2016 Alsobrook, II  
 2019/0367994 A1 12/2019 Chang  
 2020/0149115 A1 5/2020 Dobak et al.  
 2020/0289099 A1 9/2020 Palmer et al.  
 2020/0308649 A1 10/2020 Dobak et al.  
 2020/0308657 A1 10/2020 Dobak et al.  
 2020/0319205 A1 10/2020 Dobak et al.  
 2020/0383665 A1 12/2020 Palmer et al.

2020/0407800 A1 12/2020 Dobak et al.  
 2021/0196247 A1 7/2021 Palmer et al.  
 2021/0198749 A1 7/2021 Chang  
 2021/0222246 A1 7/2021 Dobak et al.  
 2021/0222247 A1 7/2021 Dobak et al.  
 2021/0222258 A1 7/2021 Chang  
 2021/0246514 A1 8/2021 Chang  
 2022/0162682 A1 5/2022 Dobak et al.

FOREIGN PATENT DOCUMENTS

WO WO-2005100603 A2 10/2005  
 WO WO-2007124072 A2 11/2007  
 WO WO-2008137772 A1 11/2008  
 WO WO-2009140550 A2 11/2009  
 WO WO-2010025341 A2 3/2010  
 WO WO-2010097773 A1 9/2010  
 WO WO-2014176446 A1 10/2014  
 WO WO-2014210467 A1 12/2014  
 WO WO-2016014705 A1 1/2016  
 WO WO-2016179043 A1 11/2016  
 WO WO-2017165199 A1 9/2017  
 WO WO-2018191268 A1 10/2018  
 WO WO-2019161126 A1 8/2019  
 WO WO-2019183620 A1 9/2019  
 WO WO-2019217478 A1 11/2019  
 WO WO-2020008192 A2 1/2020  
 WO WO-2020198229 A1 10/2020  
 WO WO-2020206085 A1 10/2020  
 WO WO-2022115487 A1 6/2022

OTHER PUBLICATIONS

Childs. Noninvasive gene expression testing in amelanotic melanoma. *JAMA Dermatol* 154(2):223-224(2018).  
 Co-pending U.S. Appl. No. 29/770,783, inventors Dobak; John et al., filed Feb. 16, 2021.  
 Co-pending U.S. Appl. No. 29/770,784, inventors Dobak; John et al., filed Feb. 16, 2021.  
 Co-pending U.S. Appl. No. 29/770,785, inventors Dobak; John et al., filed Feb. 16, 2021.  
 Co-pending U.S. Appl. No. 29/796,477, inventor Dobak; John, filed Jun. 24, 2021.  
 Dalbe et al. Multiscale Stick-Slip Dynamics of Adhesive Tape Peeling. *Phys Rev Lett* 115(12):128301 (2015).  
 De Zotti et al. Bending to Kinetic Energy Transfer in Adhesive Peel Front Microinstability. *Phys Rev Lett* 122(6):068005 (2019).  
 Ferris et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. *Dermatology Online J* 25(5):pii (May 2019).  
 Ferris et al. Noninvasive analysis of high-risk driver mutations and gene expression profiles in primary cutaneous melanoma. *J Invest Dermatol* 139:1127-1134 (2019).  
 Ferris et al. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. *Melanoma Res* 28(5):478-482 (2018).  
 Ferris et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. *JAMA Dermatol* 153(7):675-680 (2017).  
 Gerami et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. *J Am Acad Dermatol* 76(1):114-120.e2 (2017).  
 Hornberger et al. Clinical and economic implications of a noninvasive molecular pathology assay for early detection of melanoma. *JAMA Dermatol* 154(9):1-8 (2018).  
 Instructions for use DermTech adhesive skin biopsy kit. DermTech. Available at <http://dermtech.com/wp-content/uploads/2015/10/dermtech-ifu-skin-collection-v7.pdf> (Revised data Oct. 2015) (1 pg.).  
 Itoh et al. Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs). *PLoS One* 8(10):e77673 (2013).

(56)

**References Cited**

## OTHER PUBLICATIONS

Jansen et al. Gene expression analysis differentiates melanomas from Spitz nevi. *J Drugs Dermatol* 17(5):574-576 (2018).

Liu et al. Inhibition of p38 MAPK signaling augments skin tumorigenesis via NOX2 driven ROS generation. *PLoS One* 9(5):e97245 (2014).

Neagu et al. miRNAs in the Diagnosis and Prognosis of Skin Cancer. *Front Cell Dev Biol* 8:71 (2020) .

PCT/US2016/30287 International Search Report and Written Opinion dated Aug. 16, 2016.

Rivers et al. Non-invasive gene expression testing to rule out melanoma. *Skin Therapy Letter* 23(5):1-4 (2018).

Rivers et al. Ruling out Melanoma: A practical guide to improving performance through non-invasive gene expression testing. *Skin Therapy Letter: Family Practice Edition* 14(1):4-6 (2019).

Shen et al., Epigenetic and genetic dissections of UV-induced global gene dysregulation in skin cells through multi-omics analyses. *Scientific Reports* 7:42646 (2017).

Shen et al., Transcriptome analysis identifies the dysregulation of ultraviolet target genes in human skin cancers. *PLoS One* 11 (9):e0163054 [1-14] (2016).

Siegel et al. Further consideration of the pigmented lesion assay-reply. *JAMA Dermatol* 155(3):393-394 (2019).

Thoroddsen et al. Stick-slip substructure in rapid tape peeling. *Phys Rev Lett* 82(4 Pt 2):046107 (2010).


Torres et al. MicroRNA Ratios Distinguish Melanomas from Nevi. *J Invest Dermatol.* 140(1 ):164-173.e7 (2020).

Wachsmann et al. Differentiation of melanoma from dysplastic nevi in suspicious pigmented skin lesions by non-invasive tape stripping. *Journal of Dermatology* 127(Supp 1s):S145 (2007).

Yao et al. An adhesive patch-based skin biopsy device for molecular diagnostics and skin microbiome studies. *J Drugs Dermatol* 16:979-986 (2017).

Yao et al. Analytical Characteristics of a Noninvasive Gene Expression Assay for Pigmented Skin Lesions. *Assay Drug Del Technol* 14(6):355-363 (2016).

\* cited by examiner



**Dermitech**

P: 959.460.4222 | F: 959.304.2100 | [dermitech.com](http://dermitech.com)  
 11080 N. Tansy Pines Road, Suite 100 | La Jolla, CA 92037

PLA (Pigmented Lesion Assay) plus  
**MOLECULAR PATHOLOGY REPORT**



**PATIENT INFORMATION**





Patient Name:	EMD / Accn ID:
Reference #:	Body Site:
MRN #:	Date Collected:
DOB (Age):	Date Received:
Sex:	Date Reported:
Referring Physician:	Fax Number:
Address:	City/State/Zip:

**TEST RESULTS**


<b>GENE EXPRESSION RISK STATUS:</b>	LINC00518:
	PRAME:
<b>MUTATION RISK STATUS:</b>	TERT Promoter:

Expression of LINC00518 and/or PRAME is found in melanoma with a histopathologic diagnosis of melanoma. If one or both of the genes are detected, the test is positive. High Risk driver mutations in the TERT promoter region are found in early cutaneous and metastatic melanoma. The presence of mutations in TERT gene promoter are associated with in situ and invasive melanoma.

**Risk Status Interpretation:**

-  **LOW (GREEN):** Melanoma-associated gene expression and mutation risk status negative. Consider surveillance per standard of care.
-  **MODERATE (ORANGE):** Positive for LINC00518 alone has a sensitivity of 84%. Positive for PRAME alone has a sensitivity of 83%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
-  **HIGH (RED):** Positive for LINC00518 and PRAME combined have a sensitivity of 91%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
-  **Plus(+):** Positive for TERT alone has a sensitivity of 73%. TERT promoter mutations convey additional risk and probability of melanoma beyond LINC00518 or PRAME. Consider complete removal to full depth and breadth with clear margins.

**FIG. 1**



**Dermatech**

P: 858.450.4222 | F: 858.264.2100 | [dermatech.com](http://dermatech.com)  
 11000 N. Torrey Pines Road, Suite 100 | La Jolla, CA 92037



PLA (Pigmented Lesion Assay) plus  
**MOLECULAR PATHOLOGY REPORT**

PATIENT INFORMATION			
Patient Name:		Kit/ID / Accn ID:	
Reference #:		Body Site:	
MRN #:		Date Collected:	
DOB (Age):		Date Received:	
Sex:		Date Reported:	
Referring Physician:		Fax Number:	
Address:		City/State/Zip:	

**TEST RESULTS**

<b>GENE EXPRESSION RISK STATUS:</b>	<b>LINC00518:</b>
<b>MUTATION RISK STATUS:</b>	<b>TERT Promoter:</b>

Expression of LINC00518 and/or PRAME is found in lesions with a histopathologic diagnosis of melanoma. If one or both of the genes are detected, the test is positive. High Risk driver mutations in the TERT promoter region are found in early cutaneous and metastatic melanoma. The presence of mutations in TERT gene promoter are associated with in situ and invasive melanoma.

Risk Status Interpretation:	
	<b>LOW (GREEN):</b> Melanoma-associated gene expression and mutation risk status negative. Consider surveillance per standard of care.
	<b>MODERATE (ORANGE):</b> Positive for LINC00518 alone has a sensitivity of 84%. Positive for PRAME alone has a sensitivity of 83%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
	<b>HIGH (RED):</b> Positive for LINC00518 and PRAME combined have a sensitivity of 91%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
	<b>Plus(+):</b> Positive for TERT alone has a sensitivity of 73%. TERT promoter mutations convey additional risk and probability of melanoma beyond LINC00518 or PRAME. Consider complete removal to full depth and breadth with clear margins.

FIG. 2